Nina Louise Jebsen Selected Research

LTX-315

1/2021	Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors.
6/2019	Enhanced T-lymphocyte infiltration in a desmoid tumor of the thoracic wall in a young woman treated with intratumoral injections of the oncolytic peptide LTX-315: a case report.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nina Louise Jebsen Research Topics

Disease

3	Neoplasms (Cancer) 01/2021 - 03/2017
1	Necrosis 01/2021
1	Pneumonia (Pneumonitis) 06/2019
1	Hypersensitivity (Allergy) 06/2019
1	Aggressive Fibromatosis (Desmoid) 06/2019
1	Giant Cell Tumor of Bone 03/2017
1	Sarcoma (Soft Tissue Sarcoma) 03/2017

Drug/Important Bio-Agent (IBA)

2	LTX-315IBA 01/2021 - 06/2019
2	Peptides (Polypeptides)IBA 01/2021 - 06/2019
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2021
1	InterferonsIBA 06/2019
1	ChemokinesIBA 06/2019
1	CytokinesIBA 06/2019
1	Denosumab FDA Link 03/2017

Therapy/Procedure

2	Injections 01/2021 - 06/2019
1	Aftercare (After-Treatment) 01/2021
1	Subcutaneous Injections 06/2019
1	Immunotherapy 06/2019
1	Therapeutics 03/2017